H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

In Washington, even widely hailed programs with bipartisan support — like the rare pediatric disease priority review voucher ...

Results of prespecified analyses, presented at the American College of Cardiology Scientific Session, found that tafamidis ...

Japan approved BridgeBio’s acoramidis (Beyonttra) for ATTR-CM, with AstraZeneca’s Alexion handling commercialization. BridgeBio will receive a $30 million milestone payment and low double ...

BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company has a market cap of $6.61 billion, a PE ratio of -12.20 and a beta of 1.07.

Amvuttra is entering the ATTR cardiomyopathy market behind products from Pfizer that have become the standard of care and a BridgeBio Pharma drug approved last fall. But Amvuttra introduces a new ...

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage ...

BridgeBio Pharma, Inc. PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical ...